Trial · NCT02959918
Participant flow42
How many started, completed or left each group, period by period.
1 to 20 of 42
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | SEL-037 (Pegadricase) Low Dose | 3 | |
| Overall Study | STARTED | SEL-037 (Pegadricase) High Dose | 3 | |
| Overall Study | STARTED | SEL-212: SEL-110 (0.05 mg/kg) + SEL-037 Low Dose for 3 Doses Then SEL-037 Low Dose for 2 Doses | 9 | |
| Overall Study | STARTED | SEL-212: SEL-110 (0.05 mg/kg) + SEL-037 High Dose for 3 Doses Then SEL-037 High Dose for 2 Doses | 10 | |
| Overall Study | STARTED | SEL-212: SEL-110 (0.08 mg/kg) + SEL-037 Low Dose for 3 Doses Then SEL-037 Low Dose for 2 Doses | 6 | |
| Overall Study | STARTED | SEL-212: SEL-110 (0.08 mg/kg) + SEL-037 High Dose for 3 Doses Then SEL-037 High Dose for 2 Doses | 11 | |
| Overall Study | STARTED | SEL-212: SEL-110 (0.1 mg/kg) + SEL-037 Low Dose for 3 Doses Then SEL-037 Low Dose for 2 Doses | 11 | |
| Overall Study | STARTED | SEL-212: SEL-110 (0.1 mg/kg) + SEL-037 High Dose for 3 Doses Then SEL-037 High Dose for 2 Doses | 12 | |
| Overall Study | STARTED | SEL-212: SEL-110 (0.125 mg/kg) + SEL-037 High Dose for 3 Doses Then SEL-037 High Dose for 2 Doses | 14 | |
| Overall Study | STARTED | SEL-212: SEL-110 (0.15 mg/kg) + SEL-037 Low Dose for 3 Doses Then SEL-037 Low Dose for 2 Doses | 13 | |
| Overall Study | STARTED | SEL-212: SEL-110 (0.15 mg/kg) + SEL-037 High Dose for 3 Doses Then SEL-037 High Dose for 2 Doses | 14 | |
| Overall Study | STARTED | SEL-212: SEL-110 (0.15 mg/kg) + SEL-037 Low Dose for 5 Doses | 23 | |
| Overall Study | STARTED | SEL-212: SEL-110 0.15 mg/kg + SEL-037 Low 1 Dose Then SEL-110 0.1 mg/kg + SEL-037 Low for 4 Doses | 11 | |
| Overall Study | STARTED | SEL-212: SEL-110 (0.1 mg/kg) + SEL-037 Low Dose for 5 Doses | 12 | |
| Overall Study | COMPLETED | SEL-037 (Pegadricase) Low Dose | 0 | |
| Overall Study | COMPLETED | SEL-037 (Pegadricase) High Dose | 0 | |
| Overall Study | COMPLETED | SEL-212: SEL-110 (0.05 mg/kg) + SEL-037 Low Dose for 3 Doses Then SEL-037 Low Dose for 2 Doses | 1 | |
| Overall Study | COMPLETED | SEL-212: SEL-110 (0.05 mg/kg) + SEL-037 High Dose for 3 Doses Then SEL-037 High Dose for 2 Doses | 1 | |
| Overall Study | COMPLETED | SEL-212: SEL-110 (0.08 mg/kg) + SEL-037 Low Dose for 3 Doses Then SEL-037 Low Dose for 2 Doses | 1 | |
| Overall Study | COMPLETED | SEL-212: SEL-110 (0.08 mg/kg) + SEL-037 High Dose for 3 Doses Then SEL-037 High Dose for 2 Doses | 5 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02959918/flow